GILEAD SCIENCES, INC. Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities
GILEAD SCIENCES, INC. (GILD) reported Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-02-24
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2024-12-31 was -$230.00M.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2024-03-31 was $400.00M.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2019-12-31 was -$15.00M, a 139.47% decline year-over-year.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for the quarter ending 2019-09-30 was $0.00.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2024 was $270.00M, a 542.86% increase from fiscal 2023.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2023 was $42.00M, a 320.00% increase from fiscal 2022.
- GILEAD SCIENCES, INC. unrecognized tax benefits, decrease resulting from settlements with taxing authorities for fiscal 2022 was $10.00M, a 64.29% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 3 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 6 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 9 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | -$230.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $270.00M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $500.00M 10-Q · filed 2024-11-12 | ||||
| 2024-03-31 | $400.00M 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $42.00M 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | $10.00M 10-K · filed 2025-02-28 | ||||
| 2021-12-31 | $28.00M 10-K · filed 2024-02-23 | ||||
| 2020-12-31 | $454.00M 10-K · filed 2023-02-22 | ||||
| 2019-12-31 | -$15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | -$15.00M derived: sum of 2 quarters · filed 2022-02-23 | -$15.00M derived: sum of 3 quarters · filed 2022-02-23 | $104.00M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $119.00M 10-Q · filed 2019-11-05 | $157.00M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $119.00M 10-Q · filed 2019-08-06 | $157.00M derived: sum of 3 quarters · filed 2021-02-25 | ||
| 2019-03-31 | $119.00M 10-Q · filed 2019-05-08 | $157.00M derived: sum of 2 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $38.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $774.00M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $736.00M 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $706.00M 10-Q · filed 2018-11-06 | ||||
| 2017-12-31 | $12.00M 10-K · filed 2020-02-25 | ||||
| 2016-12-31 | $49.00M 10-K · filed 2019-02-26 | ||||
| 2015-12-31 | $24.00M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $5.00M 10-K · filed 2017-02-27 | ||||
| 2013-12-31 | $39.00M 10-K · filed 2016-02-24 | $38.84M 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-25 | ||||
| 2011-12-31 | $3.07M 10-K · filed 2014-02-25 | -$3.07M 10-K · filed 2012-02-23 | |||
| 2011-06-30 | $5.80M 10-Q · filed 2011-08-05 | ||||
| 2010-12-31 | $2.16M 10-K · filed 2013-02-27 | -$2.16M 10-K · filed 2011-02-28 | |||
| 2009-12-31 | -$31.52M 10-K · filed 2012-02-23 | ||||
| 2008-12-31 | -$10.25M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |